Figure 1
Flow diagram of subject disposition and response rates for the avatrombopag double-blind and extension studies. *Continued grade 3 or 4 thrombocytopenia (lack of efficacy); responders indicates those subjects with a PC response of ≥50 × 109/L with ≥20 × 109/L increase above baseline at day 28; durable response indicates PC response at ≥75% of their platelet assessments over the last 14 weeks; overall response indicates stable response or response at any ≥2 consecutive visits. In total, there were 28 (53%) and 40 (76%) subjects with durable and overall responses, respectively. SAE, serious adverse event.
